MCID: VTR013
MIFTS: 61

Vitreoretinopathy, Neovascular Inflammatory

Categories: Genetic diseases, Eye diseases, Rare diseases

Aliases & Classifications for Vitreoretinopathy, Neovascular Inflammatory

MalaCards integrated aliases for Vitreoretinopathy, Neovascular Inflammatory:

Name: Vitreoretinopathy, Neovascular Inflammatory 57 75 29 13 6 40
Proliferative Vitreoretinopathy 57 12 75 15 73
Adniv 57 59 75
Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy 59 37
Vrni 57 75
Pvr 57 75
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant; Adniv 57
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant 57
Neovascular Inflammatory Vitreoretinopathy Autosomal Dominant 75
Proliferative Vitreoretinopathy; Pvr 57
Vitreoretinopathy, Proliferative 44
Proliferative Vitreo-Retinopathy 73
Vitreoretinopathy Proliferative 55
Retinitis Proliferans 12

Characteristics:

Orphanet epidemiological data:

59
autosomal dominant neovascular inflammatory vitreoretinopathy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal dominant (11q13)


HPO:

32
vitreoretinopathy, neovascular inflammatory:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

OMIM 57 193235
Disease Ontology 12 DOID:9719
MeSH 44 D018630
SNOMED-CT 68 193364004 232016005
Orphanet 59 ORPHA329211
ICD10 via Orphanet 34 H35.2
KEGG 37 H01798

Summaries for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot : 75 Vitreoretinopathy, neovascular inflammatory: An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

MalaCards based summary : Vitreoretinopathy, Neovascular Inflammatory, also known as proliferative vitreoretinopathy, is related to microvascular complications of diabetes 1 and poliomyelitis. An important gene associated with Vitreoretinopathy, Neovascular Inflammatory is CAPN5 (Calpain 5), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Triamcinolone and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are abnormal electroretinogram and retinal detachment

OMIM : 57 Autosomal dominant neovascular inflammatory vitreoretinopathy is a blinding disorder that shares some clinical features with retinitis pigmentosa (see 268000), uveitis, and proliferative diabetic retinopathy (see 603933). Features include prominent ocular inflammation; vascular dropout, large spots of hyperpigmentation, and neovascularization of the peripheral and posterior retina; vitreous hemorrhage; and retinal detachment (summary by Sheffield et al., 1992). (193235)

Related Diseases for Vitreoretinopathy, Neovascular Inflammatory

Diseases related to Vitreoretinopathy, Neovascular Inflammatory via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 29.1 CCL2 CTGF FGF2 HGF TGFB2
2 poliomyelitis 11.1
3 paralytic poliomyelitis 11.0
4 andersen cardiodysrhythmic periodic paralysis 10.9
5 cleft lip/palate-ectodermal dysplasia syndrome 10.9
6 congenital bile acid synthesis defect 10.9
7 agraphia 10.9
8 fish allergy 10.9
9 heart conduction disease 10.9
10 cardiac tamponade 10.9
11 tooth ankylosis 10.9
12 enterocele 10.9
13 prolapse of female genital organ 10.9
14 basilar artery insufficiency 10.9
15 ovarian cystic teratoma 10.9
16 urethral diverticulum 10.9
17 preretinal fibrosis 10.7 GFAP TGFB2
18 cornea cancer 10.6 FGF2 GFAP
19 peyronie disease 10.6 TGFB1 TGFB2
20 kidney hypertrophy 10.5 CTGF TGFB1
21 laryngitis 10.5 FGF2 TGFB1
22 cholecystolithiasis 10.5 CTGF TGFB1
23 tuberculoid leprosy 10.4 TGFB1 TGFB2
24 chronic myocardial ischemia 10.4 FGF2 HGF
25 stiff skin syndrome 10.4 CTGF TGFB1 TGFB2
26 retinitis 10.4
27 microvascular complications of diabetes 3 10.4 CTGF MALAT1 TGFB1
28 retinal detachment 10.3
29 neuroma 10.2 FGF2 GFAP TGFB1
30 uveitis 10.2 CAPN5 CCL2 TGFB2
31 melorheostosis 10.2 FGF2 SPARC
32 peyronie's disease 10.2 CCL2 TGFB1 TGFB2
33 ureteral disease 10.1 CCL2 CTGF TGFB1
34 nephrosclerosis 10.1 CCL2 CTGF TGFB1
35 urinary tract obstruction 10.1 CCL2 CTGF TGFB1
36 idiopathic interstitial pneumonia 10.1 CCL2 CTGF TGFB1
37 urinary system disease 10.1 CCL2 CTGF TGFB1
38 hydrocephalus 10.0 GFAP TGFB1 TGFB2
39 chondrosarcoma 10.0 CTGF FGF2 SPARC
40 microvascular complications of diabetes 2 10.0
41 diabetic foot ulcers 10.0 TGFB1 TIMP1
42 macular holes 10.0 ADM CCL2 TGFB2
43 telangiectasis 9.9
44 tuberous sclerosis 9.9
45 mesangial proliferative glomerulonephritis 9.9 CCL2 FGF2
46 angiomatous meningioma 9.8 FGF2 GFAP
47 microvascular complications of diabetes 5 9.8
48 retinal disease 9.8
49 retinal degeneration 9.8
50 microcystic meningioma 9.8 GFAP TIMP1

Graphical network of the top 20 diseases related to Vitreoretinopathy, Neovascular Inflammatory:



Diseases related to Vitreoretinopathy, Neovascular Inflammatory

Symptoms & Phenotypes for Vitreoretinopathy, Neovascular Inflammatory

Symptoms via clinical synopsis from OMIM:

57
Eyes:
blindness
retinal detachment
vitreous hemorrhage
neovascular inflammatory vitreoretinopathy
prominent ocular inflammation
more
Lab:
distinct b-wave abnormality on electrooculography


Clinical features from OMIM:

193235

Human phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

32 (show all 9)
# Description HPO Frequency HPO Source Accession
1 abnormal electroretinogram 32 HP:0000512
2 retinal detachment 32 HP:0000541
3 uveitis 32 HP:0000554
4 blindness 32 HP:0000618
5 large hyperpigmented retinal spots 32 HP:0007658
6 vitreoretinopathy 32 HP:0007773
7 posterior retinal neovascularization 32 HP:0007778
8 vitreous hemorrhage 32 HP:0007902
9 peripheral retinal neovascularization 32 HP:0030667

GenomeRNAi Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.47 TGFB2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.47 TGFB2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.47 CAPN5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.47 TGFB2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.47 CAPN5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.47 TGFB2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.47 TGFB2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.47 CAPN5 TGFB1 TGFB2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.47 TGFB2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.47 TGFB1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.47 CAPN5
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.47 CAPN5

MGI Mouse Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ADM CTGF FGF2 GFAP HGF TGFB1
2 hematopoietic system MP:0005397 9.61 ADM FGF1 FGF2 HGF SPARC TGFB1
3 homeostasis/metabolism MP:0005376 9.32 VTN ADM CTGF FGF1 FGF2 GFAP

Drugs & Therapeutics for Vitreoretinopathy, Neovascular Inflammatory

Drugs for Vitreoretinopathy, Neovascular Inflammatory (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
2
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
3
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
4 Anti-Inflammatory Agents Phase 4,Phase 3
5 glucocorticoids Phase 4,Phase 3
6 Hormone Antagonists Phase 4,Phase 3
7 Hormones Phase 4,Phase 3
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
9 Peripheral Nervous System Agents Phase 4,Phase 3
10 triamcinolone acetonide Phase 4,Phase 3
11 Triamcinolone diacetate Phase 4,Phase 3
12 Triamcinolone hexacetonide Phase 4,Phase 3
13 Dermatologic Agents Phase 4
14 Anesthetics Phase 4
15 Anesthetics, Local Phase 4
16 Central Nervous System Depressants Phase 4,Not Applicable
17 Immunosuppressive Agents Phase 4,Phase 3
18
Colchicine Approved Phase 3 64-86-8 6167 2833
19
Dalteparin Approved Phase 3 9005-49-6
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
21
Fluorouracil Approved Phase 3 51-21-8 3385
22
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
23
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
24 Antimitotic Agents Phase 3
25 Antirheumatic Agents Phase 3
26 Anticoagulants Phase 3
27 Antiemetics Phase 3
28 Antineoplastic Agents, Hormonal Phase 3
29 Autonomic Agents Phase 3
30 BB 1101 Phase 3
31 calcium heparin Phase 3
32 Calcium, Dietary Phase 3
33 Dexamethasone acetate Phase 3 1177-87-3
34 Fibrinolytic Agents Phase 3
35 Gastrointestinal Agents Phase 3
36 Heparin, Low-Molecular-Weight Phase 3
37 HIV Protease Inhibitors Phase 3
38
protease inhibitors Phase 3
39 Antimetabolites Phase 3
40 Antimetabolites, Antineoplastic Phase 3
41 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
42
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
43 Angiogenesis Inhibitors Phase 2,Not Applicable
44 Angiogenesis Modulating Agents Phase 2,Not Applicable
45
Temazepam Approved, Investigational Not Applicable 846-50-4 5391
46 Anti-Anxiety Agents Not Applicable
47 GABA Agents Not Applicable
48 GABA Modulators Not Applicable
49 Hypnotics and Sedatives Not Applicable
50 Neurotransmitter Agents Not Applicable

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Isotretinoin for Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
3 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
4 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
5 The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Unknown status NCT00371020 Phase 3 low molecular weight heparin, 5-FU
6 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
7 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
8 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
9 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
10 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Recruiting NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
11 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study Recruiting NCT02873026 Phase 3 Triamcinolone Acetonide
12 Bevacizumab Against Recurrent Retinal Detachment Unknown status NCT02192970 Phase 2 Bevacizumab
13 Dacorin for Proliferative Vitreoretinopathy Completed NCT02865031 Phase 1, Phase 2 Decorin
14 Stem Cell Therapy for Outer Retinal Degenerations Recruiting NCT02903576 Phase 1, Phase 2
15 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Unknown status NCT01959568 Not Applicable
16 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619 Not Applicable
17 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Unknown status NCT02748421 Not Applicable
18 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
19 Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments Completed NCT01255293 Not Applicable
20 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586 Not Applicable Bevacizumab
21 23 Gauge and 20 Gauge Vitrectomy for Rhegmatogenous Retinal Detachments Completed NCT01716507 Not Applicable
22 Adaptive Optics in PVR Recruiting NCT03551574
23 Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment Active, not recruiting NCT03542162 Not Applicable
24 Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria Not yet recruiting NCT02871531 Not Applicable

Search NIH Clinical Center for Vitreoretinopathy, Neovascular Inflammatory

Cochrane evidence based reviews: vitreoretinopathy, proliferative

Genetic Tests for Vitreoretinopathy, Neovascular Inflammatory

Genetic tests related to Vitreoretinopathy, Neovascular Inflammatory:

# Genetic test Affiliating Genes
1 Vitreoretinopathy, Neovascular Inflammatory 29 CAPN5

Anatomical Context for Vitreoretinopathy, Neovascular Inflammatory

MalaCards organs/tissues related to Vitreoretinopathy, Neovascular Inflammatory:

41
Eye, Retina, Endothelial, Placenta, Monocytes

Publications for Vitreoretinopathy, Neovascular Inflammatory

Articles related to Vitreoretinopathy, Neovascular Inflammatory:

(show top 50) (show all 579)
# Title Authors Year
1
Clinicopathologic Correlation of a Subretinal Proliferative Vitreoretinopathy Band in a Patient with Chronic Recurrent Retinal Detachment. ( 29928223 )
2018
2
Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target. ( 29246578 )
2018
3
ASSOCIATION STUDY BETWEEN POLYMORPHISMS OF THE p53 AND LYMPHOTOXIN ALPHA (LTA) GENES AND THE RISK OF PROLIFERATIVE VITREORETINOPATHY/RETINAL DETACHMENT IN A MEXICAN POPULATION. ( 28106707 )
2018
4
Anterior proliferative vitreoretinopathy in a patient with Coats disease. ( 29487831 )
2018
5
Postoperative aqueous humour flare as a surrogate marker for proliferative vitreoretinopathy development. ( 29068530 )
2018
6
The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy. ( 28600710 )
2017
7
The effects of pleiotrophin in proliferative vitreoretinopathy. ( 28083679 )
2017
8
Outcomes of Vitrectomy in Pediatric Retinal Detachment with Proliferative Vitreoretinopathy. ( 28840039 )
2017
9
[The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy]. ( 29165406 )
2017
10
Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy. ( 29049737 )
2017
11
Biological Involvement of MicroRNAs in Proliferative Vitreoretinopathy. ( 28706757 )
2017
12
Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial. ( 28237428 )
2017
13
SUBRETINAL TRANSPLANTATION OF AN AUTOLOGOUS RETINAL FREE FLAP FOR CHRONIC RETINAL DETACHMENT WITH PROLIFERATIVE VITREORETINOPATHY WITH AND WITHOUT MACULAR HOLE. ( 29293208 )
2017
14
Substance P prevents development of proliferative vitreoretinopathy in mice by modulating TNF-I+. ( 29296073 )
2017
15
STAINING-ASSISTED REMOVAL OF SILICONE OIL FOR THE IDENTIFICATION OF SUBCLINICAL PROLIFERATIVE VITREORETINOPATHY. ( 28045788 )
2017
16
Preoperative aqueous humour flare values do not predict proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 28077370 )
2017
17
Proliferative Vitreoretinopathy in Treated Retinoblastoma. ( 28435935 )
2017
18
Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. ( 27600720 )
2017
19
CHOROIDAL THICKNESS CHANGES AFTER VITRECTOMY WITH SILICONE OIL TAMPONADE FOR PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT. ( 28033232 )
2016
20
Retinal Detachment and Proliferative Vitreoretinopathy. ( 26501375 )
2016
21
Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes. ( 27294805 )
2016
22
Clinical management of proliferative vitreoretinopathy: an update. ( 25602631 )
2015
23
Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy. ( 26305530 )
2015
24
[Role of Chlamydia trachomatis intraocular infection in the development of proliferative vitreoretinopathy (experimental study)]. ( 25872387 )
2015
25
Strategic planning ensures surgical success in cases of proliferative vitreoretinopathy. ( 25707039 )
2015
26
Preparation and evaluation of a novel biodegradable long-acting intravitreal implant containing ligustrazine for the treatment of proliferative vitreoretinopathy. ( 25557298 )
2015
27
Effect of different fixative solutions on eyes with experimental proliferative vitreoretinopathy. ( 25670226 )
2015
28
THE PATHOGENY OF PROLIFERATIVE VITREORETINOPATHY. ( 26978867 )
2015
29
ENDOSCOPY-ASSISTED VITRECTOMY AND MEMBRANE DISSECTION OF ANTERIOR PROLIFERATIVE VITREORETINOPATHY FOR CHRONIC HYPOTONY AFTER PREVIOUS RETINAL DETACHMENT REPAIR. ( 26562564 )
2015
30
Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy. ( 25766782 )
2015
31
The Effects of OzurdexAr (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy. ( 25721986 )
2015
32
Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis. ( 25834397 )
2015
33
BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project. ( 25991504 )
2015
34
Dashed line relaxing retinotomy in the management of retinal detachment with anterior proliferative vitreoretinopathy. ( 25897197 )
2015
35
Anatomic and functional outcomes of retinectomy for the management of complicated retinal detachment with proliferative vitreoretinopathy. ( 26491338 )
2015
36
Upregulation of TGF-A91 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition. ( 23680864 )
2014
37
Deferred laser photocoagulation of relaxing retinotomies under silicone oil tamponade to reduce recurrent macular detachment in severe proliferative vitreoretinopathy. ( 24638256 )
2014
38
Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? ( 24412519 )
2014
39
Proliferative vitreoretinopathy. ( 25196769 )
2014
40
Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. ( 24022401 )
2014
41
Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment. ( 25104737 )
2014
42
Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables. ( 25075124 )
2014
43
A TGF-I^ receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. ( 24742493 )
2014
44
Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. ( 24556886 )
2014
45
Kininogen 1 and insulin-like growth factor binding protein 6: candidate serum biomarkers of proliferative vitreoretinopathy. ( 23808406 )
2014
46
Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. ( 24556753 )
2014
47
Disease pathways in proliferative vitreoretinopathy: an ongoing challenge. ( 24604697 )
2014
48
Role of retinal pigment epithelial cell I^-catenin signaling in experimental proliferative vitreoretinopathy. ( 24656918 )
2014
49
Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy. ( 24999720 )
2014
50
Comparison of morphologic features of macular proliferative vitreoretinopathy and idiopathic epimacular membrane. ( 24736464 )
2014

Variations for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

75
# Symbol AA change Variation ID SNP ID
1 CAPN5 p.Arg243Leu VAR_069277 rs397514601
2 CAPN5 p.Leu244Pro VAR_069278 rs397514602

ClinVar genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh37 Chromosome 11, 76826469: 76826469
2 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh38 Chromosome 11, 77115423: 77115423
3 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh37 Chromosome 11, 76826472: 76826472
4 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh38 Chromosome 11, 77115426: 77115426
5 CAPN5 NM_004055.4(CAPN5): c.865C> T (p.Arg289Trp) single nucleotide variant Pathogenic rs886041303 GRCh37 Chromosome 11, 76826606: 76826606
6 CAPN5 NM_004055.4(CAPN5): c.865C> T (p.Arg289Trp) single nucleotide variant Pathogenic rs886041303 GRCh38 Chromosome 11, 77115560: 77115560
7 CAPN5 NM_004055.4(CAPN5): c.1894C> A (p.Leu632Ile) single nucleotide variant Likely benign rs111264315 GRCh38 Chromosome 11, 77123841: 77123841
8 CAPN5 NM_004055.4(CAPN5): c.1894C> A (p.Leu632Ile) single nucleotide variant Likely benign rs111264315 GRCh37 Chromosome 11, 76834887: 76834887

Expression for Vitreoretinopathy, Neovascular Inflammatory

Search GEO for disease gene expression data for Vitreoretinopathy, Neovascular Inflammatory.

Pathways for Vitreoretinopathy, Neovascular Inflammatory

Pathways related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
2
Show member pathways
13.73 CAPN5 CCL2 CTGF FGF1 FGF2 GFAP
3
Show member pathways
13.45 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
4
Show member pathways
13.39 CCL2 CTGF FGF1 FGF2 HGF TGFB1
5
Show member pathways
13.28 CCL2 CTGF FGF1 FGF2 HGF TGFB1
6
Show member pathways
13.25 CCL2 FGF1 FGF2 HGF TGFB1 TIMP1
7
Show member pathways
13.22 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
8
Show member pathways
13.17 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
9
Show member pathways
13.16 CCL2 CTGF FGF1 FGF2 HGF TGFB1
10
Show member pathways
12.96 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
11
Show member pathways
12.8 CCL2 CTGF FGF1 FGF2 HGF TGFB1
12 12.76 FGF1 FGF2 HGF TGFB1 TGFB2
13 12.68 FGF1 FGF2 HGF TGFB1 TGFB2
14
Show member pathways
12.68 FGF1 FGF2 HGF TGFB1 TGFB2
15
Show member pathways
12.57 CAPN5 FGF2 SPARC TGFB1 TGFB2 TIMP1
16
Show member pathways
12.42 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
17 12.21 FGF2 HGF TGFB1 TGFB2 VTN
18 12.16 CTGF SPARC TGFB1 TGFB2
19 12.07 CTGF FGF1 TGFB1 TGFB2
20 12.02 HGF TGFB1 TGFB2
21 11.97 FGF2 HGF TGFB1
22 11.92 CCL2 GFAP TGFB1
23 11.86 SPARC TGFB1 VTN
24 11.86 CCL2 FGF2 HGF TGFB1 TIMP1
25 11.83 CCL2 TGFB1 TGFB2
26 11.78 CCL2 TGFB1 TGFB2
27
Show member pathways
11.77 CCL2 CTGF FGF1 FGF2 HGF TGFB1
28
Show member pathways
11.68 TGFB1 TGFB2 VTN
29
Show member pathways
11.64 FGF2 TGFB1 VTN
30 11.62 FGF2 TGFB1 TGFB2
31 11.58 SPARC TIMP1 VTN
32 11.53 SPARC TGFB1 TGFB2 VTN
33 11.47 FGF2 TGFB1 TGFB2
34 11.45 CCL2 HGF TGFB1 TGFB2
35 11.45 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
36 11.42 FGF1 FGF2 HGF TGFB1
37
Show member pathways
11.38 TGFB1 TGFB2
38 11.22 HGF TGFB1 TGFB2
39 11.11 FGF2 TGFB1
40 11.08 CCL2 TIMP1
41 10.97 CCL2 CTGF FGF1 FGF2 HGF TGFB1
42 10.95 CCL2 TIMP1
43 10.9 HGF TGFB1

GO Terms for Vitreoretinopathy, Neovascular Inflammatory

Cellular components related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 ADM CCL2 CTGF FGF1 FGF2 HGF
2 extracellular matrix GO:0031012 9.56 TGFB1 TGFB2 TIMP1 VTN
3 basement membrane GO:0005604 9.5 SPARC TIMP1 VTN
4 extracellular space GO:0005615 9.36 ADM CCL2 CTGF FGF1 FGF2 HGF
5 platelet alpha granule lumen GO:0031093 9.35 HGF SPARC TGFB1 TGFB2 TIMP1

Biological processes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.93 ADM SPARC TGFB1 TGFB2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 CCL2 CTGF FGF2 TGFB1
3 cell proliferation GO:0008283 9.92 FGF1 HGF TGFB1 TGFB2 VTN
4 cell migration GO:0016477 9.91 CTGF TGFB1 TGFB2 VTN
5 extracellular matrix organization GO:0030198 9.89 FGF2 GFAP SPARC VTN
6 peptidyl-tyrosine phosphorylation GO:0018108 9.87 FGF1 FGF2 HGF
7 response to hypoxia GO:0001666 9.87 ADM TGFB1 TGFB2
8 aging GO:0007568 9.86 ADM CTGF TGFB1 TIMP1
9 activation of MAPK activity GO:0000187 9.85 FGF1 FGF2 HGF
10 positive regulation of protein phosphorylation GO:0001934 9.85 CTGF FGF1 HGF TGFB1
11 cytokine-mediated signaling pathway GO:0019221 9.85 CCL2 FGF2 HGF TGFB1 TIMP1
12 phosphatidylinositol phosphorylation GO:0046854 9.84 FGF1 FGF2 HGF
13 positive regulation of protein kinase B signaling GO:0051897 9.84 FGF1 FGF2 HGF TGFB1
14 response to organic substance GO:0010033 9.83 ADM TGFB1 TIMP1
15 lung development GO:0030324 9.83 CTGF FGF1 SPARC
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 HGF TGFB1 VTN
17 MAPK cascade GO:0000165 9.83 CCL2 FGF1 FGF2 HGF TGFB1
18 fibroblast growth factor receptor signaling pathway GO:0008543 9.82 CTGF FGF1 FGF2
19 neural tube closure GO:0001843 9.81 ADM TGFB1 TGFB2
20 angiogenesis GO:0001525 9.8 CCL2 CTGF FGF1 FGF2 TGFB2
21 positive regulation of MAP kinase activity GO:0043406 9.78 FGF1 FGF2 TGFB1
22 positive regulation of angiogenesis GO:0045766 9.78 ADM FGF1 FGF2 HGF
23 response to peptide hormone GO:0043434 9.77 CTGF SPARC TIMP1
24 inner ear development GO:0048839 9.75 SPARC TGFB1 TGFB2
25 animal organ regeneration GO:0031100 9.74 ADM HGF TGFB1
26 platelet degranulation GO:0002576 9.72 HGF SPARC TGFB1 TGFB2 TIMP1
27 positive regulation of sprouting angiogenesis GO:1903672 9.69 FGF1 FGF2
28 positive regulation of collagen biosynthetic process GO:0032967 9.69 CTGF TGFB1
29 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.69 TGFB1 TGFB2
30 epithelial to mesenchymal transition GO:0001837 9.69 HGF TGFB1 TGFB2
31 cell-cell junction organization GO:0045216 9.68 TGFB1 TGFB2
32 cell growth GO:0016049 9.68 TGFB1 TGFB2
33 cell activation GO:0001775 9.68 TGFB1 TIMP1
34 hyaluronan catabolic process GO:0030214 9.67 FGF2 TGFB1
35 positive regulation of cell division GO:0051781 9.67 FGF1 FGF2 TGFB1 TGFB2
36 pathway-restricted SMAD protein phosphorylation GO:0060389 9.66 TGFB1 TGFB2
37 salivary gland morphogenesis GO:0007435 9.65 TGFB1 TGFB2
38 wound healing GO:0042060 9.65 FGF2 SPARC TGFB1 TGFB2 TIMP1
39 neuron projection regeneration GO:0031102 9.63 ADM GFAP
40 heart valve morphogenesis GO:0003179 9.62 TGFB1 TGFB2
41 negative regulation of macrophage cytokine production GO:0010936 9.58 TGFB1 TGFB2
42 positive regulation of cell proliferation GO:0008284 9.56 ADM CTGF FGF1 FGF2 HGF TGFB1
43 response to wounding GO:0009611 9.55 ADM CTGF GFAP TGFB1 TGFB2
44 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.49 FGF1 FGF2
45 regulation of signaling receptor activity GO:0010469 9.28 ADM CCL2 CTGF FGF1 FGF2 HGF
46 signal transduction GO:0007165 10.22 ADM CAPN5 CCL2 CTGF FGF1 FGF2

Molecular functions related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.67 FGF1 FGF2 HGF
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.63 FGF1 FGF2 HGF
3 heparin binding GO:0008201 9.62 CTGF FGF1 FGF2 VTN
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 FGF1 FGF2 HGF
5 cytokine activity GO:0005125 9.55 CCL2 FGF2 TGFB1 TGFB2 TIMP1
6 fibroblast growth factor receptor binding GO:0005104 9.48 FGF1 FGF2
7 BMP receptor binding GO:0070700 9.43 TGFB1 TGFB2
8 type II transforming growth factor beta receptor binding GO:0005114 9.37 TGFB1 TGFB2
9 integrin binding GO:0005178 9.35 CTGF FGF1 FGF2 GFAP VTN
10 type III transforming growth factor beta receptor binding GO:0034714 9.26 TGFB1 TGFB2
11 growth factor activity GO:0008083 9.17 CTGF FGF1 FGF2 HGF TGFB1 TGFB2

Sources for Vitreoretinopathy, Neovascular Inflammatory

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....